Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches

被引:22
作者
Abrams, LS
Skee, DM
Wong, FA
Anderson, NJ
Leese, PT
机构
[1] RW Johnson Pharmaceut Res Inst, Raritan, NJ 08869 USA
[2] Innovex Inc, Lenexa, KS USA
关键词
D O I
10.1177/00912700122012788
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The primary objective of this open-label study was to determine the pharmacokinetics of norelgestromin (NGMN) and ethinyl estradiol (EE)following two consecutive applications of a contraceptive patch (ORTHO EVRA(TM)/EVRA(TM)). Twelve healthy women wore the first patch on their abdomen for 7 days and, after removal at 168 hours (day 7), wore a second patch for 10 days (i.e., 3 days beyond the intended 7-day wear period). Blood samples were collected before and at various times up to 456 hours (day 19) after application of the first patch for analysis of NGMN and EE. Mean serum concentrations of NGMN and EE remained within the reference ranges, 0.6 to 1.2 ng/ml and 25 to 75 pg/ml, respectively, during the entire 7-day wear period after application of the first patch and for 10 days after application of the second patch; reference ranges are based on studies with ORTHO-CYCLEN(R)/Cilest(R). No patch detached spontaneously. No subject discontinued or experienced a serious adverse event.
引用
收藏
页码:1232 / 1237
页数:6
相关论文
共 17 条
[1]  
Abrams L, 2000, FASEB J, V14, pA1479
[2]  
Abrams LS, 2000, CLIN PHARMACOL THER, V67, P105
[3]  
Abrams LS, 2000, CLIN PHARMACOL THER, V67, P106
[4]   Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive - A randomized controlled trial [J].
Audet, MC ;
Moreau, M ;
Koltun, WD ;
Waldbaum, AS ;
Shangold, G ;
Fisher, AC ;
Creasy, GW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (18) :2347-2354
[5]  
CORSON SL, 1994, AM J OBSTET GYNECOL, V170, P1556
[6]   Contraceptive failure rates: New estimates from the 1995 National Survey of Family Growth [J].
Fu, HS ;
Darroch, JE ;
Haas, T ;
Ranjit, N .
FAMILY PLANNING PERSPECTIVES, 1999, 31 (02) :56-63
[7]   DRUG ABSORPTION IN GASTROINTESTINAL-DISEASE AND SURGERY - CLINICAL PHARMACOKINETIC AND THERAPEUTIC IMPLICATIONS [J].
GUBBINS, PO ;
BERTCH, KE .
CLINICAL PHARMACOKINETICS, 1991, 21 (06) :431-447
[8]  
HEDON B, 2000, INT J GYNECOL OBS S1, V70, P78
[9]   Unintended pregnancy in the United States [J].
Henshaw, SK .
FAMILY PLANNING PERSPECTIVES, 1998, 30 (01) :24-+
[10]   PHARMACOLOGICAL AND PHARMACOKINETIC CHARACTERISTICS OF NORGESTIMATE AND ITS METABOLITES [J].
MCGUIRE, JL ;
PHILLIPS, A ;
HAHN, D ;
TOLMAN, EL ;
FLOR, S ;
KAFRISSEN, ME .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (06) :2127-2131